EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Differential ex vivo susceptibility of Plasmodium malariae and Plasmodium falciparum clinical isolates from Ghana and Mali to current and lead discovery candidate antimalarial drugs

Alamissa Soulama, Fanta Sogore, Felix Ansah, Ousmaila Diakite, Jersley D Chirawurah, Fatoumata O Maiga, Mohamed Maiga, Harry A Danwonno, Brice Campo, Abdoulaye A Djimde, Gordon A Awandare, Lucas N Amenga-Etego und 2 weitere

Microbiology Spectrum · 2025-04 · 13 (4)

DOI: 10.1128/spectrum.02176-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025-04. Verfasst von Alamissa Soulama und 13 weiteren Autor:innen. Beteiligte Einrichtung: West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Legon, Ghana. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, Plasmodium malariae, Malaria. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-falciparum species causing malaria in humans are considered neglected in the fight toward malaria elimination. Recent data highlight the increasing contribution of Plasmodium malariae to malaria morbidity and mortality. In this study, the susceptibility of P. malariae and Plasmodium falciparum to current antimalarial drugs was compared to advanced lead candidate drugs using field isolates. The blood samples were collected from the Central region of Ghana and Faladje and Kati in Mali. Following this, an ex vivo drug efficacy assay was conducted by screening mono-infected isolates against a panel of antimalarials. In Ghana, the susceptibility of the two species to most of the current antimalarial drugs was comparable, except for artemether, sulfadoxine, and atovaquone, for which the drugs were less potent against P. malariae than P. falciparum (7.12 vs 2.15 nM, 25.72 vs 7.86 nM, and 10.38 vs 2.51 nM, respectively). In Mali, quinine was significantly more potent against P. malariae than P. falciparum (18.35 and 26.84 nM), and tafenoquine was less potent against P. malariae than P. falciparum (5.50 and 2.85 nM). Among the candidate drugs, except INE963, whose inhibitory potency was comparable between both species, the other compounds significantly inhibited P. malariae more than P. falciparum . The data showed that current drugs investigated against the isolates from Ghana may be suitable for curing P. malariae infections. However, in Mali, chloroquine resistance appeared to have affected the suitability of quinine-based compounds for non-falciparum malaria treatment. Therefore, additional studies are required to establish the efficacy of artemether-lumefantrine for the treatment of P. malariae infections. IMPORTANCE One major hurdle to research in the community is our inability to have continuous culture for parasites such as Plasmodium malariae and Plasmodium ovale . These two are common in the West African region and co-occur with Plasmodium falciparum in driving both clinical or asymptomatic infections as either mono-infections or mixed infections. This manuscript is a buildup of our efforts at using ex vivo methods to study the susceptibility of P. malariae and P. falciparum to conventional and lead compounds, comparing the isolates from Ghana and Mali. This is necessary to facilitate drug discovery efforts in combating malaria holistically. The community will greatly see this work as a step in the right direction, stimulating more research into these other parasites causing malaria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsPlasmodium falciparumPlasmodium malariaeMalariaGhanaMaliHumansMalaria, FalciparumParasitic Sensitivity TestsDrug ResistanceDrug Discovery

Stichwörter der Autor:innen

Plasmodiumantimalarial agentsmalarianon-falciparum

Substanzen

Antimalarials

Autor:innen und Institutionen

  • West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Legon, Ghana.
  • Faculty of Pharmacy, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Malaria Research and Training Centre (MRTC), Bamako, Mali.
  • Medicines for Malaria Venture (MMV), Geneva, Switzerland.

ORCID-Profile: Laurent Dembele, Yaw Aniweh

Zitieren

APA

Soulama, A., Sogore, F., Ansah, F., Diakite, O., Chirawurah, J. D., Maiga, F. O., Maiga, M., Danwonno, H. A., Campo, B., Djimde, A. A., Awandare, G. A., Amenga-Etego, L. N., Dembele, L., & Aniweh, Y. (2025). Differential ex vivo susceptibility of Plasmodium malariae and Plasmodium falciparum clinical isolates from Ghana and Mali to current and lead discovery candidate antimalarial drugs. Microbiology Spectrum, 13(4). https://doi.org/10.1128/spectrum.02176-24

Vancouver

Soulama A, Sogore F, Ansah F, Diakite O, Chirawurah JD, Maiga FO, et al. Differential ex vivo susceptibility of Plasmodium malariae and Plasmodium falciparum clinical isolates from Ghana and Mali to current and lead discovery candidate antimalarial drugs. Microbiology Spectrum. 2025;13(4). doi:10.1128/spectrum.02176-24

BibTeX
@article{Soulama2025,
  author = {Soulama, Alamissa and Sogore, Fanta and Ansah, Felix and Diakite, Ousmaila and Chirawurah, Jersley D and Maiga, Fatoumata O and Maiga, Mohamed and Danwonno, Harry A and Campo, Brice and Djimde, Abdoulaye A and Awandare, Gordon A and Amenga-Etego, Lucas N and Dembele, Laurent and Aniweh, Yaw},
  title = {Differential ex vivo susceptibility of Plasmodium malariae and Plasmodium falciparum clinical isolates from Ghana and Mali to current and lead discovery candidate antimalarial drugs},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {4},
  doi = {10.1128/spectrum.02176-24}
}
Kostenlos starten →